Recruiting Clinical Trials

Displaying 81 - 90 of 227 result(s)
Study Title Condition Phase Location
A Randomized, Participant and Investigator Blinded, Sponsor Open-label, Placebo-controlled, Single Dose Study to Investigate the Safety and Tolerability of XXB750 in Heart Failure Participants With Reduced Ejection Fraction (HFrEF) Heart Failure With Reduced Ejection Fraction (HFrEF) Phase 1
  • Country: 
    United States
  • Country: 
    Netherlands
A Single-arm, Prospective, Multicentre, Open-label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient-reported Outcomes (PRO) in Patients With Relapsing Multiple Sclerosis (RMS) Transitioning From Fumarate-based RMS Approved Therapies o ... Relapsing Multiple Sclerosis Phase 3
  • Country: 
    Argentina
  • Country: 
    Australia
  • Country: 
    Greece
  • Country: 
A 24-month, Open-label, Prospective, Multicenter Interventional, Single-arm Study Assessing the Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Relapsing Multiple Sclerosis (RMS) Patients in China Relapsing Multiple Sclerosis (RMS) Phase 4
  • Country: 
    China
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib Relapsing Multiple Sclerosis Phase 3
  • Country: 
    United States
  • Country: 
    Argentina
  • Country: 
    Belgium
  • Country: 
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament ... Relapsing-Remitting Multiple Sclerosis Phase 4
  • Country: 
    United States
  • Country: 
    Canada
Phase I, Open Label, Multicenter, Dose Escalation Study of YTB323 in Adult Patients With CLL/SLL, DLBCL and ALL Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Diffuse Large B-cell Lymphoma; Acute Lymphoblastic Leukemia Phase 1
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    Austria
  • Country: 
Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen (Relapsing-remitting Multiple Sclerosis and Active Secondary Progressive Multiple Sclerosis) Relapsing-remitting Multiple Sclerosis, Active Secondary Progressive Multiple Sclerosis Not Given
  • Country: 
    Japan
A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase Multiple Sclerosis Phase 3
  • Country: 
    Belarus
  • Country: 
    France
  • Country: 
    Poland
  • Country: 
A Randomized, Controlled, Multicenter, Open-label Trial Comparing a Hospital Post-discharge Care Pathway Involving Aggressive LDL-C Management That Includes Inclisiran With Usual Care Versus Usual Care Alone in Patients With a Recent Acute Coronary S ... Acute Coronary Syndrome Phase 3
  • Country: 
    United States
AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Naïve, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes. Relapse Remitting Multiple Sclerosis Phase 4
  • Country: 
    United States
  • Country: 
    Puerto Rico